Radiopharmaceutical Sciences
A section of Pharmaceuticals (ISSN 1424-8247).
Section Information
The aim of Radiopharmaceutical Sciences section of the journal is to provide academic and industrial communities with open access to publications on development of primarily novel radiopharmaceuticals and their application for fundamental and applied studies in biology and medicine. The development of the radiopharmaceuticals considers the design, synthesis and radiolabeling of the agents, their biological and preclinical evaluation, and finally clinical application. Contributions may concern targeted, pre-targeted, and non-targeted radiopharmaceuticals ranging from small molecules via peptides, peptidomimetics and antibodies and derivatives thereof to particles for their use in gamma scintigraphy including single photon emission tomography (SPECT), positron emission tomography (PET) and endoradiotherapy. The field of diagnostic imaging and (radio)pharmaceutical therapy guided by the diagnostic imaging is of strong interest. The related topics of physics, dosimetry, radiopharmacy, and hybrid imaging are also accepted. Download Section Flyer
Keywords
- Radiopharmaceuticals, agents, probes
- Radionuclides
- Imaging biomarkers
- Biological/preclinical evaluation
- First in-human clinical studies
- SPECT, PET/CT, PET/MRI
- Labeling chemistry
- Medicinal radiochemistry, (pre)clinical radiopharmacology, and radiopharmacy including GMP-compliant production
- Radiopharmaceutical drug development
- Radiotheranostics
- Hybrid imaging
- Organic molecules, high-molecular weight biomolecules, nano- and microparticles
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Molecular Imaging of the Tumor Microenvironment (Deadline: 30 November 2024)
- In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research, 2nd Edition (Deadline: 30 December 2024)
- Innovative Approaches to Radiopharmaceuticals: Advances in Design, Labeling, and Applications (Deadline: 31 January 2025)
- Development of Novel Radiopharmaceuticals for SPECT and PET Imaging (Deadline: 24 February 2025)
- 20th Anniversary of Pharmaceuticals—Advances in Radiopharmaceutical Sciences and Nuclear Medicine (Deadline: 25 February 2025)
- Radiopharmaceuticals and Nanotechnology (Deadline: 25 February 2025)
- The Medical Applications of Novel PET Radiopharmaceuticals (Deadline: 25 February 2025)
- Recent Advancements in Radiochemistry and PET Radiotracer Development: 2nd Edition (Deadline: 25 February 2025)
- Past, Present and Future Radiotracer Techniques: Radiopharmaceuticals in Cancer Theranostics (Deadline: 28 February 2025)
- Development of Radiolabeled Peptides (Deadline: 25 March 2025)
- Antibody-Based Imaging and Targeted Therapy in Cancer (Deadline: 31 March 2025)
- Progress in the Development and Medical Applications of PET/SPECT Radiotracers and Theranostics (Deadline: 31 March 2025)
- In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research: New Advances (Deadline: 25 April 2025)
- Production, Development and Theranostic Applications of Radiopharmaceuticals for Nuclear Medicine (Deadline: 25 April 2025)
- Challenges in the Development of PET and SPECT Radiotracers: Innovative Ideas with Negative Outcomes (Deadline: 25 September 2025)
- PET/CT for Diagnosis, Treatment Planning and Prognosis Prediction in Oncology and Inflammatory Diseases (Deadline: 31 December 2025)
